# US 2023/0271978 A1 · Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0271978 A1
- Document ID: US20230271978A1
- Status: Published application
- Kind: A1
- Application number: 18/095,621
- Filed: 2023-01-11
- Published: 2023-08-31
- Earliest claimed: 2022-01-12
- Assignees: Denali Therapeutics Inc.
- Applicants: Denali Therapeutics Inc.
- Inventors: Anantha Sudhakar
- Web page: https://patentgrep.com/patent/US20230271978A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.

## Claims

### Claim 1

A crystalline form selected from the group consisting of:
Form A of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;
Form B of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;
Form C of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;
Form D of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;
Form E of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; and
Form F of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide.

### Claim 2

A crystalline form of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, characterized as Form A.

### Claim 3 (depends on 2)

The crystalline form of claim 2, having an X-ray powder diffraction pattern derived using Cu (Kα) radiation comprising three, four, five, six, seven or more peaks, in term of 2-theta degrees, selected from the group consisting of: 6.9, 11.5, 13.0, 13.9, 16.6, 19.4, 23.4, and 24.0±0.2 degrees.

### Claim 4 (depends on 2)

The crystalline form of claim 2, having an X-ray powder diffraction pattern is substantially in accordance with that shown in FIG. 1.

### Claim 5 (depends on 2)

The crystalline form of claim 2, characterized by a differential scanning calorimetry (DSC) curve with an onset at about 186.7° C. and an endothermic peak at 188.9° C.

### Claim 6 (depends on 2)

The crystalline form of claim 2, is characterized as having one or more of:
a) an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 1;
b) an X-ray powder diffraction (XRPD) pattern derived using Cu (Kα) radiation with peaks, in term of 2-theta degrees, at about 6.9, 13.0, 16.6, and 23.4±0.2 degrees;
c) a Differential Scanning Calorimetry (DSC) thermogram substantially the same as shown in FIG. 2;
d) a Differential Scanning Calorimetry (DSC) thermogram with three endothermic events having an onset at about 186.7° C. and a peak at about 188.9° C.;
e) a Thermogravimetric Analysis (TGA) pattern substantially the same as shown in FIG. 2;
f) a Thermogravimetric Analysis (TGA) pattern with an about 1.0% w/w loss from about 27.8° C. to about 150° C.; or
g) combinations thereof.

### Claim 7

A crystalline form of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, characterized as Form B.

### Claim 8 (depends on 7)

The crystalline form of claim 7, having an X-ray powder diffraction pattern comprising a peak, in term of 2-theta degree, at about 9.6 and 16.4±0.2 degrees.

### Claim 9 (depends on 7)

The crystalline form of claim 7, having an X-ray powder diffraction pattern derived using Cu (Kα) radiation comprising three, four, five, six or more peaks, in terms of degrees, selected from the group consisting of: 9.6, 11.5, 13.8, 16.4, 19.2, 23.2, and 23.8±0.2 degrees.

### Claim 10 (depends on 7)

The crystalline form of claim 7, having an X-ray powder diffraction pattern is substantially in accordance with that shown in FIG. 3.

### Claim 11 (depends on 7)

The crystalline form of claim 7, characterized by a differential scanning calorimetry (DSC) curve comprises an endotherm at about 189.2° C. and an endothermic peak at 191.9° C.

### Claim 12 (depends on 7)

The crystalline form of claim 7, is characterized as having one or more of:
a) an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 3;
b) an X-ray powder diffraction (XRPD) pattern derived using Cu (Kα) radiation with peaks, in term of 2-theta degrees, at about 9.6, 11.5, 16.4, 19.2, and 23.8±0.2 degrees;
c) a Differential Scanning Calorimetry (DSC) thermogram substantially the same as shown in FIG. 4;
d) a Differential Scanning Calorimetry (DSC) thermogram with three endothermic events having an onset at about 189.2° C. and a peak at about 191.9° C.;
e) a Thermogravimetric Analysis (TGA) pattern substantially the same as shown in FIG. 4;
f) a Thermogravimetric Analysis (TGA) pattern with a about 1.0% w/w loss from about 23.8° C. to about 150° C.; or
g) combinations thereof.

### Claim 13

A crystalline form of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, characterized as Form C.

### Claim 14 (depends on 13)

The crystalline form of claim 13, having an X-ray powder diffraction pattern derived using Cu (Kα) radiation comprising three, four, five, six or more peaks, in term of 2-theta degrees, selected from the group consisting of: 9.8, 10.2, 14.8, 15.2, 18.1, 20.4, and 22.3±0.2 degrees.

### Claim 15 (depends on 13)

The crystalline form of claim 13, having the X-ray powder diffraction pattern is substantially in accordance with that shown in FIG. 5.

### Claim 16 (depends on 13)

The crystalline form of claim 13, characterized by a differential scanning calorimetry (DSC) curve comprises an endotherm at about 124.9° C. and an endothermic peak at 131.3° C.

### Claim 17 (depends on 13)

The crystalline form of claim 13, is characterized as having one or more of:
a) an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 5;
b) an X-ray powder diffraction (XRPD) pattern derived using Cu (Kα) radiation with peaks, in term of 2-theta degrees, at about 9.8, 10.2, 14.8, 15.2, and 20.4±0.2 degrees;
c) a Differential Scanning Calorimetry (DSC) thermogram substantially the same as shown in FIG. 7;
d) a Differential Scanning Calorimetry (DSC) thermogram with three endothermic events having an onset at about 124.9° C. and a peak at about 131.3° C.;
e) a Thermogravimetric Analysis (TGA) pattern substantially the same as shown in FIG. 7;
f) a Thermogravimetric Analysis (TGA) pattern with a about 5.7% w/w loss from about 22.4° C. to about 100° C.; or
g) combinations thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable excipient.

### Claim 19 (depends on 18)

A pharmaceutical composition of claim 18, wherein the pharmaceutical composition further comprises one or more crystalline forms selected from the group consisting of Form A of Compound (I); Form B of Compound (I); Form C of Compound (I); and a pharmaceutically acceptable excipient.

### Claim 20 (depends on 1)

A method of treating a disease or disorder mediated by RIPK1 in a patient in need thereof, comprising administering to the patient an effective amount of the crystalline form of claim 1.
